Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

v3.10.0.1
Earnings (Loss) Per Common Share (Tables)
 3 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):
 
 
 
Three Months ended

September 30,
 
 
 
2018
 
 
2017
 
Basic and diluted numerator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss attributable to iBio, Inc. stockholders
 
$
(4,398
)
 
$
(3,826
)
Preferred stock dividends
 
 
(66
)
 
 
(66
)
Net loss available to iBio, Inc. stockholders
 
$
(4,464
)
 
$
(3,892
)
 
 
 
 
 
 
 
 
 
Basic and diluted denominator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
 
17,894
 
 
 
9,185
 
 
 
 
 
 
 
 
 
 
Per share amount
 
$
(0.25
)
 
$
(0.42
)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] As of September 30, 2018 and 2017, shares issuable which could potentially dilute future earnings were as follows:
 
 
 
Three Months Ended

September 30,
 
 
 
2018
 
 
2017
 
 
 
(in thousands)
 
Stock options
 
 
1,364
 
 
 
1,360
 
Series A Preferred
 
 
6,103
 
 
 
-
 
Series B Preferred
 
 
6,428
 
 
 
-
 
Shares excluded from the calculation of diluted loss per share
 
 
13,895
 
 
 
1,360